Physician profile
Steve C Scott
NPI 1881283059
$7,644.37
in general payments reported to CMS, 2019-2025
21 companies · $767 in 2025
The $767 reported for 2025 was more than what 75% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,113 · 2022: $505 · 2023: $1,605 · 2024: $3,655 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,968 · Education: $59.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,967.59 |
| Education | $59.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,856.33 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $1,280.05 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Medtronic, INC. | $647.82 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $586.71 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Neurocrine Biosciences, INC. | $559.39 | 2022-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $513.49 | 2023-2025 | Auvelity |
| Bard Peripheral Vascular, INC. | $452.14 | 2021 | |
| Abbvie INC. | $354.02 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $279.49 | 2024 | Fanapt, Hetlioz |
| Alkermes, INC. | $257.34 | 2023-2025 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $238.07 | 2023-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Astrazeneca Pharmaceuticals LP | $225.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $124.64 | 2022 | |
| Lundbeck LLC | $66.55 | 2024 | Rexulti, Abilify Asimtufii |
| Almatica Pharma LLC | $64.56 | 2024 | Loreev Xr |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $37.92 | 2023-2024 | Aplenzin |
| Althera Pharmaceuticals LLC | $29.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.33 | 2024 | Trintellix |
| Biogen, INC. | $16.96 | 2024 | |
| Merck Sharp & Dohme LLC | $13.43 | 2023 | Belsomra |
| Novo Nordisk INC | $12.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steve Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.